LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article: Serum galectin-1 in patients with multiple myeloma: associations with survival, angiogenesis, and biomarkers of macrophage activation.

    Andersen, Morten Nørgaard / Ludvigsen, Maja / Abildgaard, Niels / Petruskevicius, Irma / Hjortebjerg, Rikke / Bjerre, Mette / Honoré, Bent / Møller, Holger J / Andersen, Niels F

    OncoTargets and therapy

    2017  Volume 10, Page(s) 1977–1982

    Abstract: ... the macrophage activation biomarkers soluble CD163 (sCD163) and soluble mannose receptor. Serum Gal-1 levels were not ... However, serum levels of Gal-1 have never been investigated in patients with multiple myeloma (MM). We measured ... and after treatment (n=24) and examined associations of serum Gal-1 with clinicopathological ...

    Abstract Galectin-1 (Gal-1) is known to regulate cell signaling within the immune system and may be a target for new anticancer immune therapy. In patients with chronic lymphocytic leukemia (CLL) and classical Hodgkin lymphoma (cHL), high levels of Gal-1 within the tumor microenvironment were associated with worse disease state or poor outcome. Gal-1 can be secreted from cells by an unknown mechanism, and levels in blood samples were associated with high tumor burden and worse disease state in cHL and CLL patients. However, serum levels of Gal-1 have never been investigated in patients with multiple myeloma (MM). We measured serum Gal-1 levels in samples from patients with treatment demanding MM at the time of diagnosis (n=102) and after treatment (n=24) and examined associations of serum Gal-1 with clinicopathological information obtained from patient medical records, as well as data on bone marrow angiogenesis and the macrophage activation biomarkers soluble CD163 (sCD163) and soluble mannose receptor. Serum Gal-1 levels were not elevated in patients with MM at diagnosis compared with healthy donors (median values 8.48 vs 11.93 ng/mL,
    Language English
    Publishing date 2017-04-04
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2495130-4
    ISSN 1178-6930
    ISSN 1178-6930
    DOI 10.2147/OTT.S124321
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Serum galectin-1 in patients with multiple myeloma

    Andersen MN / Ludvigsen M / Abildgaard N / Petruskevicius I / Hjortebjerg R / Bjerre M / Honoré B / Møller HJ / Andersen NF

    OncoTargets and Therapy, Vol Volume 10, Pp 1977-

    associations with survival, angiogenesis, and biomarkers of macrophage activation

    2017  Volume 1982

    Abstract: ... the macrophage activation biomarkers soluble CD163 (sCD163) and soluble mannose receptor. Serum Gal-1 levels were not ... like) activation of macrophages.Keywords: galectin-1, multiple myeloma, macrophage, soluble CD163 ... with multiple myeloma (MM). We measured serum Gal-1 levels in samples from patients with treatment demanding MM ...

    Abstract Morten Nørgaard Andersen,1–3,* Maja Ludvigsen,1,3,* Niels Abildgaard,4 Irma Petruskevicius,3 Rikke Hjortebjerg,5 Mette Bjerre,5 Bent Honoré,1 Holger J Møller,2 Niels F Andersen31Department of Biomedicine, Faculty of Health, Aarhus University, 2Department of Clinical Biochemistry, 3Department of Hematology, Aarhus University Hospital, Aarhus, 4Department of Hematology, Odense University Hospital, Odense, 5Medical Research Laboratory, Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark*These authors contributed equally to this workAbstract: Galectin-1 (Gal-1) is known to regulate cell signaling within the immune system and may be a target for new anticancer immune therapy. In patients with chronic lymphocytic leukemia (CLL) and classical Hodgkin lymphoma (cHL), high levels of Gal-1 within the tumor microenvironment were associated with worse disease state or poor outcome. Gal-1 can be secreted from cells by an unknown mechanism, and levels in blood samples were associated with high tumor burden and worse disease state in cHL and CLL patients. However, serum levels of Gal-1 have never been investigated in patients with multiple myeloma (MM). We measured serum Gal-1 levels in samples from patients with treatment demanding MM at the time of diagnosis (n=102) and after treatment (n=24) and examined associations of serum Gal-1 with clinicopathological information obtained from patient medical records, as well as data on bone marrow angiogenesis and the macrophage activation biomarkers soluble CD163 (sCD163) and soluble mannose receptor. Serum Gal-1 levels were not elevated in patients with MM at diagnosis compared with healthy donors (median values 8.48 vs 11.93 ng/mL, P=0.05), which is in contrast to results in cHL and CLL. Furthermore, Gal-1 levels did not show association with bone marrow angiogenesis, clinicopathological parameters, overall survival, or response to treatment. There was a statically significant association between Gal-1 and sCD163 levels (R=0.24, P=0.02), but not with soluble mannose receptor (P=0.92). In conclusion, our results indicate that Gal-1 is not an important serum biomarker in MM, which is in contrast to data from patients with cHL and CLL. However, the association with sCD163 is in line with previous data showing that Gal-1 may be involved in alternative (M2-like) activation of macrophages.Keywords: galectin-1, multiple myeloma, macrophage, soluble CD163, soluble mannose receptor, angiogenesis
    Keywords Galectin-1 ; Multiple Myeloma ; Macrophage ; sCD163 ; sMR ; Angiogenesis. ; Neoplasms. Tumors. Oncology. Including cancer and carcinogens ; RC254-282 ; Internal medicine ; RC31-1245 ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2017-04-01T00:00:00Z
    Publisher Dove Medical Press
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top